Immune response


Select item(s)
Key Findings
In a phase2/3 trial of the ChAdOx1 nCoV-19 vaccine, immunogenecity was found to be similar across all age groups after the booster dose.
PMID 33220855
Title Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Author(s) nameRamasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group.
Journal Lancet
Impact factor43.38
Citation count26
Date of publishing2021 Dec 19
In a phase1/2 clinical trial, BBIBP-CorV inactivated vaccine given in a 2 dose regimen was found to be safe and well-tolerated. The vaccine-induced a robust humoral response in 100% of the vaccine recipients.
PMID 33069281
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Author(s) nameXia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X.
Journal Lancet Infect Dis
Impact factor21.77
Citation count17
Date of publishing2021 Jan
In a phase1/2 clinical trail, BBIBP-CorV inactivated vaccine given in a 2 dose regimen was found to be safe and well tolerated. The vaccine induced a robust humoral response 1n 100% of the vaccine recipients.
PMID 33069281
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Author(s) nameXia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X.
Journal Lancet Infect Dis
Impact factor21.77
Citation count17
Date of publishing2021 Jan
In a placebo-controlled, observer-blinded, pivotal efficacy trial, nucleoside-modified RNA vaccine BNT162b2 was found to be 95% effective in preventing COVID-19 infection.
PMID 33301246
Title Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Author(s) namePolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group.
Journal N Engl J Med
Impact factor37.91
Citation count67
Date of publishing2020 Dec 31
The INO-4800 DNA vaccine was immunogenic in 100% (38/38) of the vaccinated subjects. The vaccine elicited both cellular and humoral immune responses in all subjects.
PMID 33392485
Title Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Author(s) nameTebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, Purwar M, Sylvester A, Pawlicki J, Gillespie E, Maricic I, Zaidi FI, Kim KY, Dia Y, Frase D, Pezzoli P, Schultheis K, Smith TRF, Ramos SJ, McMullan T, Buttigieg K, Carroll MW, Ervin J, Diehl MC, Blackwood E, Mammen MP, Lee J, Dallas MJ, Brown AS, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM.
Journal EClinicalMedicine
Impact factor6.68
Citation count2
Date of publishing2020 Dec 24
In a phase 1/2 trial, NVX-CoV2373, a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine was found to be safe and elicited an immune response that exceeded levels in COVID-19 convalescent serum.
PMID 32877576
Title Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Author(s) nameKeech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM.
Journal N Engl J Med
Impact factor37.91
Citation count72
Date of publishing2020 Dec 10
In a phase I/II study of COVID-19 RNA vaccine BNT162b1 showed good immunogenicity and showed a good amount of RBD-binding IgG titers.
PMID 32785213
Title PhaseI/II study of COVID-19 RNA vaccine BNT162b1 in adults
Author(s) nameMulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU.
Journal Nature
Impact factor24.36
Citation count49
Date of publishing2020 Oct